BPC-157 vs TB-500: Two Different Molecules, and What "TB-500" Really Is
BPC-157 is a defined 15-residue peptide. "TB-500" is a different story: in chemical databases and FDA documents it is a seven-residue acetylated fragment of thymosin β4 (Ac-LKKTETQ), but commercial suppliers often use the name for full-length thymosin β4, a 43-residue protein. This guide sets out the three formal identities, explains the naming ambiguity, and states precisely what our certificates do and do not establish, including an Axiom intact-mass result and its limits.
Precise Pep Labs Research Editorial Team · November 13, 2026 · 9 min read
Key facts
- BPC-157 (15-residue, ≈ 1419.5 Da) is structurally unrelated to thymosin β4 and to the fragment sold as TB-500; it shares no sequence, length or origin with them.
- "TB-500" is two different molecules: chemical databases and an FDA evaluation define it as the seven-residue acetylated fragment Ac-LKKTETQ (≈ 889 Da), while suppliers often use the name for full-length thymosin β4 (43 residues, ≈ 4963.5 Da).
- Our Axiom certificate for Klow 80mg reports the TB-500 component at an observed intact average mass of 4963.58 Da against a theoretical 4963.506 Da (same basis, ±1 Da tolerance) — consistent with full-length thymosin β4, not the 889 Da fragment.
- That intact-mass match does not establish the full amino-acid sequence or exclude every isobaric variant, and it applies only to the Klow sample tested; sequence confirmation would need LC-MS/MS peptide mapping.
- The two BPC-157 + TB-500 blend certificates (Freedom, Kovera) name the component as thymosin β4 / TB-4 and quantify it by HPLC but carry no intact-mass data, so the Klow result is not transferred to them.
The short answer
BPC-157 and TB-500 are unrelated molecules, and "TB-500" is itself used for two different substances.
- BPC-157 is a defined 15-residue synthetic peptide (a pentadecapeptide) [1].
- TB-500, in chemical databases and in the FDA's own evaluation, is a seven-residue acetylated fragment of the larger protein thymosin β4 — the peptide Ac-LKKTETQ [3][7][8].
- Full-length thymosin β4 is a 43-residue protein, about five and a half times the mass of that fragment [2].
The naming problem is that some suppliers use "TB-500" for full-length thymosin β4 rather than for the short fragment, even though the two are structurally different. This guide sets out the formal chemical identities, explains where the commercial names diverge from them, states precisely what our laboratory certificates do and do not establish, and keeps the research for each molecule attributed to the molecule actually studied.
This is a research-use-only reference. It describes molecules and the published laboratory record. It contains no dosing, administration, recovery, or human-use information, and nothing here recommends any compound for use in people or animals.
The three molecules, by formal identity
| BPC-157 | Thymosin β4 (full length) | "TB-500" fragment (Ac-LKKTETQ) | |
|---|---|---|---|
| What it is | Synthetic 15-residue peptide | 43-residue actin-binding protein | 7-residue acetylated fragment of thymosin β4 |
| Database record | PubChem CID 9941957 [1] | PubChem CID 45382195 [2] | PubChem CID 62707662 [3] |
| Molecular formula | C62H98N16O22 | C212H350N56O78S | C38H68N10O14 |
| Average molecular mass | ≈ 1419.5 Da | ≈ 4963.5 Da | ≈ 889.0 Da |
| Origin of the name | Partial sequence of a protein from gastric juice; a stable gastric pentadecapeptide [4] | A naturally occurring cellular protein [2][5] | The actin-binding segment (residues 17–23) of thymosin β4 with an acetylated N-terminal leucine [7][8] |
Two things are immediately clear from the table. First, BPC-157 has no structural relationship to either thymosin molecule — different length, different formula, different origin. Second, the fragment that databases and the FDA call "TB-500" is not the same molecule as full-length thymosin β4: it is one short piece of it, at roughly one-fifth of the mass.
Where the commercial name diverges from the chemical name
In the formal record, the name "TB-500" points to the fragment:
- PubChem indexes "TB-500" as the 889 Da acetylated heptapeptide [3].
- An FDA staff evaluation prepared for its Pharmacy Compounding Advisory Committee describes TB-500 as "a seven amino acid synthetic fragment of thymosin beta (β4) from amino acids 17 to 23" with an acetyl group at the N-terminal leucine [8].
- The analytical-chemistry literature agrees: a method paper for detecting TB-500 states that "the key ingredient of TB-500 is the peptide LKKTETQ with artificial acetylation of the N-terminus" [7].
In the commercial market, however, material sold as "TB-500" is frequently full-length thymosin β4 (the 43-residue protein), not the fragment. Our own certificates are an example: the component is labelled "TB-500" but the measured mass (below) matches the full-length protein. The result is that the single word "TB-500" can mean either molecule depending on the source, and the two are not interchangeable. The reliable way to know which one a given vial contains is a mass or sequence measurement on that specific material.
What our certificates establish — stated precisely
Our products in this area are a BPC-157 + TB-500 blend and a standalone BPC-157. The relevant certificates differ in how far they pin down the "TB-500" component, and the differences matter.
The Klow certificate carries an intact-mass identity match
The strongest single piece of evidence comes from the Axiom Analytics certificate for our Klow 80mg blend, which includes a "TB-500 (Thymosin B4)" component. For that component the certificate reports:
- an observed intact mass of 4963.58 Da (the mean of two vials), against a theoretical mass of 4963.506 Da, a difference of +0.074 Da (about 15 ppm);
- both values expressed on the same basis — the certificate states the tolerance as "accurate mass against its identity tolerance: 4963.506 Da ± 1 Da (average)", so the comparison is an average (not monoisotopic) mass, consistent with a deconvoluted intact-mass measurement of a peptide this size;
- an identity acceptance criterion of within ±1 Da of the theoretical average mass, by LC-MS (ESI+).
That observed average mass is consistent with full-length thymosin β4 (theoretical average ≈ 4963.5 Da) and clearly inconsistent with the ≈ 889 Da seven-residue fragment. On that measurement, the component is far more likely to be the full-length protein than the fragment.
What that measurement does not do. An intact-mass match, even a close one, confirms the molecule's mass; it does not establish the complete amino-acid sequence, and it cannot by itself exclude every isobaric variant — a different structure of the same nominal mass. The certificate's identity method is a mass match to within ±1 Da; it is not a sequence determination. A sequence-informative method, such as LC-MS/MS peptide mapping (enzymatic digestion followed by analysis of the fragment ions), would be needed to confirm the actual sequence. The result is also attributed only to the sample Axiom tested: the certificate states that, unless Axiom performed the sampling, "the laboratory does not attest that the submitted sample represents the wider lot or batch."
So the accurate statement is narrow and specific: for the Klow sample tested, the "TB-500" component's measured intact average mass is consistent with full-length thymosin β4 and not with the short fragment; the sequence was not independently confirmed on that certificate.
The two BPC-157 + TB-500 blend certificates identify by name, not by intact mass
Our standalone BPC-157 + TB-500 blend certificates establish less about the TB-500 component's structure, and the article should not pretend otherwise:
- The Freedom Diagnostics certificate (accession 2607200743, BPC-157 + TB-500 10mg) names the component "Thymosin Beta-4", confirms identity by LC-MS against that name, and reports its content by HPLC. It does not print an observed intact mass.
- The Kovera Labs certificate (KVR-2026-1ED094, BPC-157 + TB-500 20mg) names the component "TB-500(TB-4)", confirms the blend identity by LC-MS, and reports per-component content by HPLC. It too prints no observed intact mass.
- The KMD Analytical certificate for our standalone BPC-157 10mg covers only the BPC-157 side.
These certificates name the component as thymosin β4 / "TB-4" and confirm it is consistent with that identity by their methods, but a name on a certificate is the laboratory reporting the supplied identity, not an independent structural proof. The Klow intact-mass result belongs to the Klow sample and cannot be transferred to these separate blends or lots, which are different samples from different laboratories without an intact-mass measurement on file. Across our products, the honest position is: the component is identified as thymosin β4, one certificate backs that with an intact-mass match on its own sample, and full structural (sequence) confirmation is not on any of these certificates.
Which molecule each study investigated
Because "TB-500" spans two molecules and BPC-157 is unrelated to both, study attribution has to be explicit. Findings for one of these molecules are not evidence for another.
- Full-length thymosin β4 has its own literature as a 43-residue cellular protein, reviewed for roles in cell biology and tissue repair [5][6]. These studies concern the full-length protein, not the Ac-LKKTETQ fragment, and not BPC-157.
- The Ac-LKKTETQ fragment ("TB-500") corresponds to the actin-binding region of thymosin β4 [7]; the clearest published work on the fragment under the name "TB-500" is analytical — methods to detect N-acetylated LKKTETQ and its metabolites, developed for equine doping control [7].
- BPC-157 is studied as a synthetic pentadecapeptide, predominantly in in-vitro and animal models, and largely by one research group [4]. There is no completed human efficacy trial establishing clinical benefit for BPC-157.
Three consequences follow, and the article holds to all three: results from full-length thymosin β4 cannot be attributed to the Ac-LKKTETQ fragment or the reverse; neither can be attributed to BPC-157; and none of this literature establishes a human clinical benefit for any of the three.
Regulatory status, briefly and by substance
This section states dated facts from primary sources and links out; it is not legal advice and implies no approval for human use. It names the exact substance each source addresses.
- TB-500 as the fragment. The FDA's May 2026 staff evaluation, prepared for its Pharmacy Compounding Advisory Committee, identifies TB-500 as the seven-amino-acid thymosin β4 fragment (residues 17–23, with an acetylated N-terminal leucine) [8]. The October 2026 HHS enforcement-discretion policy takes the same view of identity: its Appendix B defines the covered "TB-500 acetate" as the acetylated seven-residue peptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln [12][13]. A fragment-specific identity determination like these does not by itself establish what a given commercial product labeled "TB-500" contains, and does not cover full-length thymosin β4 or any other molecule marketed under that name.
- HHS 503A compounding policy (October 2026). On October 30, 2026, HHS announced a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," under which it does not intend to pursue enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds a drug product under section 503A using one of six listed peptides — BPC-157 and TB-500 among them — when ten stated conditions are met [12][13]. This is not FDA marketing approval; it does not add any peptide to the final 503A bulks list, which remains subject to rulemaking; and HHS states that it creates no rights and may be revisited. By its own terms the policy does not extend to research-use-only substances, and its conditions include eligibility, sourcing and manufacturing, identity and characterization, certificate-of-analysis and labeling requirements, together with a single-active-ingredient limit — none of which describes a research-use-only, multi-component blend. Nothing in it authorizes any retailer to market these substances for use in people.
- Compounding safety information. The FDA also maintains dated information on bulk drug substances that may present significant safety risks in compounding, and a list of substances evaluated under section 503A; the status of these peptides has moved through that process and should be checked against the current FDA list [9][10].
- BPC-157. BPC-157 has no FDA marketing approval. It has been part of the same compounding-review process and is one of the six peptides named in the October 2026 interim policy [9][12].
- Anti-doping, separately. Apart from the FDA and HHS compounding materials, the 2026 WADA Prohibited List addresses thymosin β4 and its derivatives, including TB-500, within its scope [11]. WADA's language is broader than the seven-residue fragment, so an anti-doping listing and a compounding-identity definition are not interchangeable; confirm the exact listing for the specific substance.
Limitations
- Abstract-level sourcing. Claims were verified against published abstracts, bibliographic records and the named database and regulatory documents; full texts were not obtained for this article.
- Intact mass is not a sequence. The Klow certificate's intact-mass match is consistent with full-length thymosin β4 but does not establish the sequence or exclude every isobaric variant.
- One certificate, one sample. The intact-mass result is for the Klow sample tested and is not transferred to other lots or to the separate BPC-157 + TB-500 blends, which carry no intact-mass data.
- Commercial naming is not standardised. "TB-500" denotes the fragment in databases and FDA documents but is frequently used commercially for full-length thymosin β4; a label alone does not determine the molecule.
Where to find the certificates
The certificates referenced here are in our COA Library and linked from the relevant product pages, including the BPC-157 + TB-500 blend. Our guides to reading a certificate of analysis and purity versus net content explain what each certificate field does and does not establish. If the lot printed on a vial you hold is not listed, contact us with the lot details and we will locate the corresponding report.
Evidence from our lab reports
Each row is one certificate on file, identified by product and report date. Values are the figures the testing laboratory reported for that lot; they are not re-measured or adjusted here. "Latest COA in Library" and "Earlier COA" describe the certificate's place in the COA Library for that product. The lot currently shipping is identified by each product's inventory batch number, not by which certificate is newest.
| Product | Report date | Test | Purity | Net content | Certificate |
|---|---|---|---|---|---|
| BPC-157 10mgLatest COA in Library | Nov 3, 2026 | HPLC purity | 99.99% | 9.90 mg | View |
| BPC-157 + TB-500 10mgLatest COA in Library | Aug 5, 2026 | HPLC purity | 99.19% | 12.63 mg | View |
| BPC-157 + TB-500 20mgLatest COA in Library | Aug 5, 2026 | HPLC purity | 99.18% | 21.02 mg | View |
| Klow 80mgLatest COA in Library | Oct 15, 2026 | HPLC purity | 99.67% | 83.45 mg | View |
Frequently asked questions
- Are BPC-157 and TB-500 the same thing?
- No, and they are not even related. BPC-157 is a synthetic 15-residue peptide (about 1419.5 Da) derived from a partial sequence of a protein found in gastric juice. TB-500 is a name for a thymosin β4 species — either the seven-residue acetylated fragment Ac-LKKTETQ (about 889 Da) or, as commonly sold, full-length thymosin β4 (43 residues, about 4963.5 Da). The two share no sequence, length or origin, and research on one is not evidence about the other.
- Is TB-500 the fragment or full-length thymosin β4?
- It depends on the source. In chemical databases such as PubChem, and in the FDA's own evaluation, TB-500 is the seven-residue acetylated fragment of thymosin β4, residues 17 to 23 (Ac-LKKTETQ). Commercial suppliers, however, frequently use "TB-500" for full-length thymosin β4, which is the entire 43-residue protein. The name alone does not tell you which molecule is in a given vial; a mass or sequence measurement does.
- What does our certificate say the TB-500 component is?
- Our Axiom certificate for the Klow 80mg blend reports the component labelled "TB-500 (Thymosin B4)" at an observed intact average mass of 4963.58 Da, against a theoretical average mass of 4963.506 Da, within the laboratory's ±1 Da identity tolerance. That is consistent with full-length thymosin β4 and inconsistent with the roughly 889 Da fragment. The result applies to the sample Axiom tested.
- Does that mass measurement prove the molecule is full-length thymosin β4?
- It is strong evidence, but not complete proof. An intact-mass match confirms the molecule's mass; it does not establish the full amino-acid sequence and cannot by itself rule out every isobaric variant — a different structure of the same nominal mass. Confirming the sequence would require a sequence-informative method such as LC-MS/MS peptide mapping. The accurate statement is that the measured mass is consistent with full-length thymosin β4 for that sample, with the sequence not independently confirmed on the certificate.
- Do the BPC-157 + TB-500 blend certificates prove the TB-500 identity?
- Less so. The Freedom Diagnostics certificate names the component "Thymosin Beta-4" and the Kovera certificate names it "TB-500(TB-4)"; both confirm identity by LC-MS against that name and report content by HPLC, but neither prints an observed intact mass. They record the supplied identity and are consistent with it by their methods, but they do not independently establish the structure, and the Klow intact-mass result is a separate sample that is not transferred to them.
- Which research applies to which molecule?
- Each molecule has its own literature. Full-length thymosin β4 is studied as a 43-residue cellular protein; the Ac-LKKTETQ fragment corresponds to its actin-binding region and appears mainly in analytical detection work under the name TB-500; and BPC-157 is studied as a synthetic pentadecapeptide, largely in vitro and in animals. Findings for one of these molecules are not evidence for another, and none of this work establishes a human clinical benefit.
References
- PubChem Compound Summary for CID 9941957, BPC-157 (C62H98N16O22). National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/9941957
- PubChem Compound Summary for CID 45382195, Thymosin beta-4 (C212H350N56O78S). National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/45382195
- PubChem Compound Summary for CID 62707662, TB-500 (N-acetyl-LKKTETQ; C38H68N10O14). National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/62707662
- Sikiric P, Barisic I, Udovicic M, et al. Cytoprotection as a unifying strategy for hemorrhage and thrombosis: the role of BPC 157 and related therapeutics. Pharmaceuticals (Basel). 2026;19(3):463. doi:10.3390/ph19030463
- Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin β4. Expert Opinion on Biological Therapy. 2015;15(Suppl 1):S139–S145. doi:10.1517/14712598.2015.1011617
- Kleinman HK, Sosne G. Thymosin β4 and the anti-fibrotic switch. International Immunopharmacology. 2023;115:109628. doi:10.1016/j.intimp.2022.109628
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A. 2012;1265:57–69. doi:10.1016/j.chroma.2012.09.043
- U.S. Food and Drug Administration. TB-500 (thymosin beta-4 fragment): FDA review of a bulk drug substance nominated for use in compounding. Pharmacy Compounding Advisory Committee staff evaluation, 2026. https://www.fda.gov/media/193349/download
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- World Anti-Doping Agency. The 2026 Prohibited List. International Standard, effective 1 January 2026. https://www.wada-ama.org/en/prohibited-list
- U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice of availability, 91 FR 68526, October 30, 2026 (Docket No. HHS–OASH–2026–0496). https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
- U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy document, with Appendix A interim access list and Appendix B per-peptide identity, salt form and route limits). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
How this article was checked
- Written by: Precise Pep Labs Research Editorial Team
- Last reviewed: November 13, 2026
- Published: November 13, 2026
- Last updated: November 13, 2026
- Lab reports cited: 4
- Sources: the numbered references above and the certificates of analysis in the COA Library. Editorial content is reviewed for research-use-only compliance before publication.
Related research materials
Reference materials discussed in this article, each with its certificate of analysis
Related articles
- Research noteComparisons
CJC-1295 With DAC vs Without DAC: What the Name Actually Means
In the published literature, CJC-1295 is a long-acting molecule carrying an albumin-binding Drug Affinity Complex (DAC). Products sold as "CJC-1295 no DAC" are a different molecule, Modified GRF (1-29), without that tag. The human and animal studies behind CJC-1295's multi-day duration used the DAC form, so their results cannot be transferred to a no-DAC product. This guide separates the scientific names from the commercial labels and sets out what a certificate of analysis does and does not establish.
November 13, 2026 - Research noteComparisons
Selank vs Semax: Molecular Differences and Research Evidence
Selank and Semax share one design feature, a C-terminal Pro-Gly-Pro tail, and little else: Selank is built from the immunoglobulin fragment tuftsin, Semax from a fragment of adrenocorticotropic hormone. Most published work studies one compound or the other, so most of the two literatures cannot be compared at all. Five studies examined both within the same experiment, and those are the only sources supporting direct comparison. This guide sets out what has been compared, what has not, and what the certificates for the two products record.
November 9, 2026 - Research noteCOA and Testing
Peptide Purity vs. Net Content: Understanding the Difference
HPLC purity is the main peak's share of total peak area: it says how much of the detected peptide material is the target compound. Net peptide content is the mass of peptide in the vial, measured against a reference standard and compared with the label claim. Counter-ions, water, residual solvent and fill mass change content without changing purity, which is why a 99.99 % pure lot can measure 9.22 mg in a 10 mg vial and another lot 58.15 mg in a 50 mg vial.
November 7, 2026 - Research noteCOA and Testing
How to Read a Peptide Certificate of Analysis (COA)
A peptide certificate of analysis reports what an independent laboratory measured on one sample of one lot: identity, chromatographic purity, net content against the label claim, the methods used and the specifications applied. This guide explains each field using three genuine Precise Pep Labs certificates, and shows what a purity percentage can and cannot tell you.
November 6, 2026
